Safety and pharmacokinetics of single, dual, and triple antiretroviral drug formulations delivered by pod-intravaginal rings designed for HIV-1 prevention: A Phase I trial

Keyphrases

• Drug Formulation 100%
• Pharmacokinetics 100%
• Antiviral Drugs 100%
• Vaginal Ring 100%
• Phase I Trial 100%
• Fumarate 100%
• HIV-1 Prevention 100%
• Maraviroc 30%
• Adverse Events 15%
• HIV Pre-exposure Prophylaxis 15%
• Hispanic 10%
• African American 10%
• Colposcopy 10%
• Itch 10%
• Cervical mucus 10%
• Vaginal Tissue 10%
• Vaginal Microbiota 10%
• Tissue Biopsy 10%
• Mass Spectrometry 5%
• Drug Levels 5%
• Tenofovir Disoproxil Fumarate 5%
• Emtricitabine 5%
• HIV Prevention 5%
• Triphosphate 5%
• Epithelial Damage 5%
• Drug Concentration 5%
• Efficacy Testing 5%
• Pre-exposure Prophylaxis (PrEP) 5%
• Serious Adverse Events 5%
• Tissue Concentration 5%
• Oral Dosing 5%
• Trial Registration 5%
• Small Sample Size 5%
• Tandem Mass Spectrometry 5%
• Cross-cultural Analysis 5%
• Antiretroviral Agents 5%
• Metabolite Concentrations 5%
• Device-independent 5%
• Drug Release 5%
• Combination Regimen 5%
• Continued Use 5%
• Target Concentration 5%
• Cervicovaginal Lavage 5%
• Elastomer 5%
• Delivery Device 5%
• Vaginal Film 5%
• Triple Combination 5%
• Ring Design 5%
• Event-independent 5%
• Drug Metabolites 5%
• Tenofovir Diphosphate 5%
• Polymer-coated 5%
• Oral Films 5%
• Residual Drug 5%
• Antiretroviral Regimen 5%
• Safety Testing 5%
• Liquid Chromatographic 5%
• Safety Pharmacokinetics 5%
• Ring Group 5%
• Microbial Shifts 5%

Pharmacology, Toxicology and Pharmaceutical Science

• HIV 100%
• Drug Formulation 100%
• Phase I Trials 100%
• Fumaric Acid 100%
• Pharmacokinetics 100%
• Maraviroc 30%
• Adverse Event 20%
• Microbiome 10%
• Pruritus 10%
• Tenofovir Disoproxil 5%
• Emtricitabine 5%
• Drug Concentration 5%
• Drug Release 5%
• Tenofovir 5%
• Antiretrovirus Agent 5%
• Gelatin 5%
• Drug Metabolite 5%
• Elastomer 5%
• efficacy testing 5%